Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
October 2019
-
Media ReleaseNovartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host diseaseREACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD…
-
Media ReleaseNovartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitisNew two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
-
Media ReleaseNovartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practiceData from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
-
Media ReleaseNovartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mgResults from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
-
Key ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Media ReleaseAveXis presents updated STRONG data at WMSOlder patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
-
Key ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumPhase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
-
Media ReleaseNovartis and Microsoft announce collaboration to transform medicine with artificial intelligenceMultiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
September 2019
-
Media ReleaseNovartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthmaOnce-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,…
-
Media ReleaseNovartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthmaOnce-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical…
-
Key ReleaseNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patientsIn MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
-
Media ReleaseAveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
Pagination
- ‹ Previous page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- …
- 88
- › Next page